FDA Wants Better PDUFA Fees-Goals Alignment, Predictability
This article was originally published in Scrip
While industry wants better integration of the patient perspective into US drug development and regulatory decision-making and an enhancement of the scientific expertise, processes and tools regulators use, the FDA said it would like to see greater alignment of the fee structure with its public health goals and improved predictability of the dollar amounts under the next round of the Prescription Drug User Fee Act – PDUFA VI – according to the minutes from the first meeting to negotiate terms.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.